Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Approves Sanofi’s PD-1 Inhibitor, Teikoku’s Donepezil Tape and More
Japan’s health ministry approved a throng of new medicines and indications on December 23 including Sanofi’s PD-1 inhibitor Libtayo (cemiplimab) for the treatment of cervical cancer and Teikoku Seiyaku’s tape formulation of donepezil for Alzheimer’s. Libtayo gained the nod to…
To read the full story
Related Article
- Sanofi Launches PD-1 Inhibitor Libtayo in Japan
March 31, 2023
- Chuikyo OKs Listing of Mounjaro, Libtayo, Imjudo; 30 Billion-Plus Peak Sales for Lilly Med
March 9, 2023
- Sanofi’s Cemiplimab Backed for Approval, Third PD-1 Inhibitor in Japan
November 29, 2022
- MHLW Panel Endorses Teikoku’s Donepezil Tape for Alzheimer’s and More Drugs
November 28, 2022
REGULATORY
- Japan Panel Designates Two Ebola Therapies for Early Approval Pathway
April 1, 2026
- MHLW, METI Launch Joint Task Force to Safeguard Medical Supply Chains
April 1, 2026
- Japan Urges Priority Supply of Petroleum-Based Materials for Medical Devices
March 31, 2026
- Japan’s New HIV Cases Hit 20-Year Low in 2025
March 30, 2026
- MHLW Launches Genomic Medicine Body GeMJ
March 30, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…